Medical startups whet the appetite | Economie

HANOI (VNA) – If in 2021 medical startups like Doctor Anywhere, Medici, Med247, AiHealth are struggling to attract capital… then major transactions surged in the first half of 2022.

Doctor Anywhere agent assists customers in using the online testing service. Photo: Baodautu

Thus, EastBridge Partners, a large South Korean group with a capital of $1 billion, has invested $30 million in USM Healthcare (Vietnam). USM Healthcare is the only developer and manufacturer in Vietnam of coronary stents, as well as balloon catheters and medical supplies. USM Healthcare is expected to expand its production, research and development capabilities.

In February 2022, private equity fund Quadria Capital invested $90 million in the Con Cung mother and child supermarket chain. According to Quadria, the investment will help Con Cung expand its network and product portfolio and modernize its integrated “All-in-One” AI technology application platform to provide customized products and services to more than 5 million Vietnamese mothers and babies. In particular, Quadria will leverage its network of portfolio companies such as FV Hospital to help Con Cung enter the health and nutrition sector, as well as develop mother and child-focused products and services.

In early March 2022, Jio Health, a Vietnamese healthcare startup, announced the completion of a $20 million Series B funding round led by Singapore-based Heritas Capital, investors Fuchsia Ventures, Kasikorn Bank Group, and Monk’s Hill Ventures. It is a startup that uses advanced technologies to provide affordable, on-demand healthcare. Through a smartphone application, this platform helps doctors and nurses to check and treat patients anytime and anywhere more conveniently. With this investment, Jio Health will expand its smart clinic system and comprehensive ecosystem in Vietnam, aiming to enter regional markets in the coming years.

Meanwhile, POC Pharma raised $10.3 million in a Series A round led by the Alven Fund, along with Picus Capital, FEBE Ventures and FJ Labs. POC Pharma will use the new capital to accelerate the implementation of digital marketing solutions for the pharmaceutical industry and expand the market to countries in Southeast Asia, South Asia, the Middle East and beyond.

It can be seen that medical and pharmaceutical technologies are receiving special attention from domestic and foreign investors, as well as financial technology and e-commerce. This is a great opportunity for Vietnamese startup companies. According to forecasts, in 2022, Vietnam will spend about $ 22.7 billion on healthcare. The number of startups in this field is only 2% of the total of more than 4,000 medical technology startups in Asia.

According to market research firm Fitch Solutions, healthcare spending in Vietnam is expected to reach $23 billion in 2022. Research by Business Monitor International (BMI) has indicated that the Vietnamese pharmaceutical industry could be worth $16.1 billion by 2026. – CPV / VNA

Leave a Comment